188 related articles for article (PubMed ID: 19350128)
1. Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro.
Jiang X; Crain EJ; Luettgen JM; Schumacher WA; Wong PC
Thromb Haemost; 2009 Apr; 101(4):780-2. PubMed ID: 19350128
[No Abstract] [Full Text] [Related]
2. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.
Becker RC; Alexander JH; Newby LK; Yang H; Barrett Y; Mohan P; Wang J; Harrington RA; Wallentin LC
Thromb Haemost; 2010 Nov; 104(5):976-83. PubMed ID: 20806117
[TBL] [Abstract][Full Text] [Related]
3. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects.
Barrett YC; Wang J; Song Y; Pursley J; Wastall P; Wright R; Lacreta F; Frost C
Thromb Haemost; 2012 May; 107(5):916-24. PubMed ID: 22398784
[TBL] [Abstract][Full Text] [Related]
4. Apixaban: an oral direct factor-xa inhibitor.
Jiménez D; Yusen RD; Ramacciotti E
Adv Ther; 2012 Mar; 29(3):187-201. PubMed ID: 22354465
[TBL] [Abstract][Full Text] [Related]
5. Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma.
Luettgen JM; Knabb RM; He K; Pinto DJ; Rendina AR
J Enzyme Inhib Med Chem; 2011 Aug; 26(4):514-26. PubMed ID: 21171894
[TBL] [Abstract][Full Text] [Related]
6. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.
Zhang D; He K; Raghavan N; Wang L; Mitroka J; Maxwell BD; Knabb RM; Frost C; Schuster A; Hao F; Gu Z; Humphreys WG; Grossman SJ
Drug Metab Dispos; 2009 Aug; 37(8):1738-48. PubMed ID: 19420130
[TBL] [Abstract][Full Text] [Related]
7. The contribution of anti-Xa and anti-IIa activities to the profibrinolytic activity of low-molecular-weight heparins.
Ammollo CT; Semeraro F; Semeraro N; Colucci M
Thromb Haemost; 2009 Apr; 101(4):782-5. PubMed ID: 19350129
[No Abstract] [Full Text] [Related]
8. [Apixaban: pharmacology and action profile].
Gassanov N; Caglayan E; Er F
Dtsch Med Wochenschr; 2012 Jan; 137(4):138-41. PubMed ID: 22259168
[TBL] [Abstract][Full Text] [Related]
9. New antithrombotic drugs: potential for use in oncology.
Levine MN
J Clin Oncol; 2009 Oct; 27(29):4912-8. PubMed ID: 19738103
[TBL] [Abstract][Full Text] [Related]
10. Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties.
Orwat MJ; Qiao JX; He K; Rendina AR; Luettgen JM; Rossi KA; Xin B; Knabb RM; Wexler RR; Lam PY; Pinto DJ
Bioorg Med Chem Lett; 2014 Aug; 24(15):3341-5. PubMed ID: 24951330
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
Pinto DJ; Orwat MJ; Koch S; Rossi KA; Alexander RS; Smallwood A; Wong PC; Rendina AR; Luettgen JM; Knabb RM; He K; Xin B; Wexler RR; Lam PY
J Med Chem; 2007 Nov; 50(22):5339-56. PubMed ID: 17914785
[TBL] [Abstract][Full Text] [Related]
12. Apixaban, an oral, direct inhibitor of activated Factor Xa.
Shantsila E; Lip GY
Curr Opin Investig Drugs; 2008 Sep; 9(9):1020-33. PubMed ID: 18729009
[TBL] [Abstract][Full Text] [Related]
13. Apixaban (Eliquis)--a new oral anticoagulant for atrial fibrillation.
Med Lett Drugs Ther; 2013 Feb; 55(1409):9-10. PubMed ID: 23381226
[No Abstract] [Full Text] [Related]
14. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients.
Zafar MU; Farkouh ME; Osende J; Shimbo D; Palencia S; Crook J; Leadley R; Fuster V; Chesebro JH
Thromb Haemost; 2007 Mar; 97(3):487-92. PubMed ID: 17334518
[TBL] [Abstract][Full Text] [Related]
15. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.
Frost C; Nepal S; Wang J; Schuster A; Byon W; Boyd RA; Yu Z; Shenker A; Barrett YC; Mosqueda-Garcia R; Lacreta F
Br J Clin Pharmacol; 2013 Nov; 76(5):776-86. PubMed ID: 23451769
[TBL] [Abstract][Full Text] [Related]
16. Factor Xa inhibitors: today and beyond.
Walenga JM; Jeske WP; Hoppensteadt D; Fareed J
Curr Opin Investig Drugs; 2003 Mar; 4(3):272-81. PubMed ID: 12735228
[TBL] [Abstract][Full Text] [Related]
17. Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa.
Fevig JM; Cacciola J; Buriak J; Rossi KA; Knabb RM; Luettgen JM; Wong PC; Bai SA; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2006 Jul; 16(14):3755-60. PubMed ID: 16682200
[TBL] [Abstract][Full Text] [Related]
18. Apixaban in acute coronary syndromes.
Karthikeyan G; Eikelboom JW
Cardiovasc Ther; 2011 Oct; 29(5):285-90. PubMed ID: 20553278
[TBL] [Abstract][Full Text] [Related]
19. 1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
Pinto DJ; Orwat MJ; Quan ML; Han Q; Galemmo RA; Amparo E; Wells B; Ellis C; He MY; Alexander RS; Rossi KA; Smallwood A; Wong PC; Luettgen JM; Rendina AR; Knabb RM; Mersinger L; Kettner C; Bai S; He K; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2006 Aug; 16(15):4141-7. PubMed ID: 16730984
[TBL] [Abstract][Full Text] [Related]
20. Facts and artefacts of coagulation assays for factor Xa inhibitors.
Haas S
Thromb Haemost; 2010 Apr; 103(4):686-8. PubMed ID: 20174751
[No Abstract] [Full Text] [Related]
[Next] [New Search]